What is Obinutuzumab?

Obinutuzumab is a humanized monoclonal antibody used in combination with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the U.S. Food and Drug Administration (FDA) in November 2013 and marketed under the brand name Gazyva, with a black box warning of fatal hepatitis B virus (HBV) reactivation and fatal progressive multifocal leukoencephalopathy (PML).

Otuzumab can be used in combination with chlorambucil as a first-line treatment for chronic lymphocytic leukemia. Its progression-free survival is significantly better than rituximab in the same combination (26.7 months vs. 15.2 months, p <0.001), but its overall survival is not significantly improved (mortality rate 8% vs. 12%, p=0.08). Otuzumab It can also be used in combination with bendamustine (bendamustine) and then with otuzumab alone to treat patients with follicular lymphoma as a second-line treatment with rituximab-containing regimens. It has not been tested on pregnant women.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.